In agreement with those previous reports, we have demonstrated here a robust increase of IL-8 secretion and upregulation of CXCR1 in erlotinib-resistant lung cancer cells, compared to their parental counterparts, regardless of the mutational status of EGFR or KRAS. The gene discussed is CXCL8; the disease is lung cancer.